Selecta Bioscience, a biotechnology company specializing in the development of tolerogenic therapies, announced an agreement to license its ImmTOR platform to Takeda on Oct. 4th, 2021. Takeda will use the platform to develop gene therapies for lysosomal storage disorders.
For the use of its platform, Selecta will receive an undisclosed upfront payment and up to $1.1 billion in future additional payments. These payments are contingent on Takeda hitting specific commercial and developmental milestones in their research. Selecta is also eligible for additional royalties following commercialization of the product.
